Compare FedEx Corporation (FDX) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
FedEx Corporation vs Novartis AG — how do they compare? FedEx Corporation trades at $322.43 (market cap $75.37B), while Novartis AG trades at $153.53 (market cap $298.18B). The key difference: Novartis AG is far larger — about 4× FedEx Corporation's market cap, and Novartis AG pays the higher dividend (3.02%). Which is the better fit depends on your goals.
| FDX | NVS | |
|---|---|---|
Market Cap | $75.37B | $298.18B |
Sector | Industrials | Health |
52-Week High | $338.75 | $168.62 |
52-Week Low | $180.51 | $119.31 |
Enterprise Value | $105.00B | $339.50B |
Dividend Yield | 1.53% | 3.02% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FedEx (FDX) trades at $318.57, up 0.85% with a bullish technical signal despite mixed moving averages. The company shows solid fundamentals with a P/E of 17.17 and net income margin of 4.68%, supported by recent earnings beats. Network transformation initiatives and premium revenue mix are driving operational improvements, while analyst consensus remains strongly positive with a $360.27 price target.
Outlook remains favorable with projected revenue growth to $94.7B in 2026 and continued margin expansion. Key risks include competitive pressures in logistics and macroeconomic sensitivity. The stock offers value with reasonable valuation metrics and strong institutional support, though investors should monitor execution of cost-saving initiatives and freight demand trends.
Novartis (NVS) trades at $156.33, up 1.37% on the day, with a bullish technical signal and strong support near $156. The company reported Q2 2026 earnings that beat expectations, driven by robust oncology drug sales, and reaffirmed full-year guidance. Revenue for 2025 was $56.67 billion with a net income margin of 22.5%, while valuation ratios like P/E of 23.61 and P/B of 7.15 reflect premium pricing. Recent news highlights institutional buying and CEO confidence in the growth pipeline.
The outlook for NVS is positive, supported by earnings momentum and a diversified drug portfolio, but risks include generic competition for Entresto and pricing pressures. Analyst consensus is mixed with 24% buy ratings, indicating cautious optimism. Investment appeal hinges on execution of new drug launches and offsetting legacy product declines.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About FedEx Corporation
FedEx pioneered overnight delivery in 1973 and remains the world's largest express package provider. In its fiscal 2020 (ended May 2020), FedEx derived 51% of revenue from its express division, 33% from ground, and 10% from freight, its asset-based less-than-truckload shipping segment. The remainder comes from other services, including FedEx Office, which provides document production/shipping, and FedEx Logistics, which provides global forwarding. FedEx acquired Dutch parcel delivery firm TNT Express in 2016. TNT was previously the fourth-largest global parcel delivery provider.
Read more on FDX →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
